Free Trial
NYSE:EBS

Emergent Biosolutions (EBS) Stock Price, News & Analysis

Emergent Biosolutions logo
$6.81 +0.19 (+2.87%)
As of 01:40 PM Eastern

About Emergent Biosolutions Stock (NYSE:EBS)

Key Stats

Today's Range
$6.65
$6.91
50-Day Range
$4.74
$7.08
52-Week Range
$4.02
$15.10
Volume
348,330 shs
Average Volume
1.72 million shs
Market Capitalization
$369.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.33
Consensus Rating
Buy

Company Overview

Emergent Biosolutions Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
86th Percentile Overall Score

EBS MarketRank™: 

Emergent Biosolutions scored higher than 86% of companies evaluated by MarketBeat, and ranked 141st out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Emergent Biosolutions has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Emergent Biosolutions has received no research coverage in the past 90 days.

  • Read more about Emergent Biosolutions' stock forecast and price target.
  • Earnings Growth

    Earnings for Emergent Biosolutions are expected to grow in the coming year, from ($0.63) to $2.07 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Emergent Biosolutions is -2.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Emergent Biosolutions is -2.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Emergent Biosolutions has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Emergent Biosolutions' valuation and earnings.
  • Percentage of Shares Shorted

    15.39% of the float of Emergent Biosolutions has been sold short.
  • Short Interest Ratio / Days to Cover

    Emergent Biosolutions has a short interest ratio ("days to cover") of 6.6.
  • Change versus previous month

    Short interest in Emergent Biosolutions has recently increased by 2.04%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Emergent Biosolutions does not currently pay a dividend.

  • Dividend Growth

    Emergent Biosolutions does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    15.39% of the float of Emergent Biosolutions has been sold short.
  • Short Interest Ratio / Days to Cover

    Emergent Biosolutions has a short interest ratio ("days to cover") of 6.6.
  • Change versus previous month

    Short interest in Emergent Biosolutions has recently increased by 2.04%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Emergent Biosolutions has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Emergent Biosolutions this week, compared to 5 articles on an average week.
  • Search Interest

    Only 1 people have searched for EBS on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Emergent Biosolutions insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $49,417.00 in company stock.

  • Percentage Held by Insiders

    Only 1.20% of the stock of Emergent Biosolutions is held by insiders.

  • Percentage Held by Institutions

    78.40% of the stock of Emergent Biosolutions is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Emergent Biosolutions' insider trading history.
Receive EBS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Emergent Biosolutions and its competitors with MarketBeat's FREE daily newsletter.

EBS Stock News Headlines

Emergent BioSolutions Inc. (EBS) - Yahoo Finance
Thirty-Year “Wonder Material” Finally Ready for Factory Floors
A Nobel-recognized material once trapped in research labs is finally ready for the real world. After a 90% cost breakthrough, this wonder-material is being tested by aerospace giants, battery developers, and chip makers alike. Now, a new briefing reveals the companies best positioned to profit from its mass adoption.
See More Headlines

EBS Stock Analysis - Frequently Asked Questions

Emergent Biosolutions' stock was trading at $9.56 at the beginning of 2025. Since then, EBS shares have decreased by 28.8% and is now trading at $6.81.

Emergent Biosolutions Inc. (NYSE:EBS) issued its quarterly earnings results on Wednesday, May, 7th. The biopharmaceutical company reported $0.71 EPS for the quarter, topping the consensus estimate of $0.49 by $0.22. The biopharmaceutical company had revenue of $222.20 million for the quarter, compared to analysts' expectations of $218.50 million. Emergent Biosolutions had a negative trailing twelve-month return on equity of 0.52% and a negative net margin of 13.63%.
Read the conference call transcript
.

Emergent Biosolutions' board approved a share buyback program on Monday, March 31st 2025, which allows the company to buy back $50,000,000 in outstanding shares, according to EventVestor. This means that the company could reacquire up to 19% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company's leadership believes its shares are undervalued.

Shares of EBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Emergent Biosolutions investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), Alibaba Group (BABA) and Moderna (MRNA).

Company Calendar

Last Earnings
5/07/2025
Today
7/08/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NYSE:EBS
Employees
2,420
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.33
High Stock Price Target
$16.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+110.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$190.60 million
Pretax Margin
-6.45%

Debt

Sales & Book Value

Annual Sales
$930.30 million
Cash Flow
$1.87 per share
Price / Cash Flow
3.64
Book Value
$8.91 per share
Price / Book
0.76

Miscellaneous

Free Float
52,541,000
Market Cap
$369.63 million
Optionable
Optionable
Beta
2.09
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NYSE:EBS) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners